Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maridebart Cafraglutide (AMG 133) in Chinese subjects with obesity or overweight
NCT06352892Phase 1Completed
- Sponsor
- Amgen
- Start
- Apr 2024
- Primary completion
- Aug 2024
- Modality
- Peptides, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of maridebart cafraglutide in obesity (2 arms), sponsored by Amgen. Primary endpoints: Maximum Observed Plasma Concentration at 120 days, Area Under the Plasma Concentration-time Curve from Time Zero to the Last Quantifiable Concentration at 120 days and 1 more. Started Apr 2024; status: completed.
02
Drugs
maridebart cafraglutide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06352892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06352892.